Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Positive Non-small Cell Lung Cancer”

269 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 269 results

Early research (Phase 1)Study completedNCT03535363
What this trial is testing

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Who this might be right for
NSCLCNon-small Cell Lung Cancer
Case Comprehensive Cancer Center 6
Testing effectiveness (Phase 2)Looking for participantsNCT06728865
What this trial is testing

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)EGFR Mutation-Positive Lung CancerBrain Metastases+2 more
Li-kun Chen 70
Testing effectiveness (Phase 2)Study completedNCT01167244
What this trial is testing

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 11
Early research (Phase 1)Study completedNCT02729298
What this trial is testing

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more
Sumitomo Pharma America, Inc. 177
Testing effectiveness (Phase 2)Active Not RecruitingNCT06194448
What this trial is testing

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Who this might be right for
Lung Cancer
AstraZeneca 76
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Large-scale testing (Phase 3)Active Not RecruitingNCT04351555
What this trial is testing

Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 358
Not applicableNot Yet RecruitingNCT06287593
What this trial is testing

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

Who this might be right for
EGF-R Positive Non-Small Cell Lung Cancer
Zhejiang University 300
Testing effectiveness (Phase 2)Ended earlyNCT05099549
What this trial is testing

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Who this might be right for
Squamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal Neoplasms+3 more
NKGen Biotech, Inc. 11
Testing effectiveness (Phase 2)UnknownNCT01391260
What this trial is testing

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
ZhuGuangYing 30
Testing effectiveness (Phase 2)Ended earlyNCT02318368
What this trial is testing

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

Who this might be right for
Non-small Cell Lung Cancer
AVEO Pharmaceuticals, Inc. 10
Large-scale testing (Phase 3)UnknownNCT02824458
What this trial is testing

Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
Sun Yat-sen University 246
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Not applicableLooking for participantsNCT06304441
What this trial is testing

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 100
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Not applicableUnknownNCT06207292
What this trial is testing

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Who this might be right for
NSCLCNSCLC Stage IVOligometastatic Disease+9 more
Radiotherapy Oncology Centre "Santa Maria" Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06970639
What this trial is testing

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Who this might be right for
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc. 380
Load More Results